Angiotensin II receptor blockade and skeletal muscle metabolism in overweight and obese adults with elevated blood pressure

Therapeutic Advances in Cardiovascular Disease

Volumn 9, Issue 2, 2015, Pages 45-50

  Boutagy, Nabil E ^a   Marinik, Elaina L ^a   Anderson, Angela S ^a   Mcmillan, Ryan P ^a   Frisard, Madlyn I ^a   Davy, Kevin P ^a   Davy, Brenda M ^a   Rivero, Jose M ^b   Hulver, Matthew W ^c  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b Heart Specialists of Southwest Virginia   (United States)

^c Virginia Tech ^*  (United States)

Author keywords

angiotensin II receptor blockade; obesity; skeletal muscle metabolism

Indexed keywords

3 HYDROXYACYL COENZYME A DEHYDROGENASE; ANGIOTENSIN RECEPTOR; CITRATE SYNTHASE; OLMESARTAN; PALMITIC ACID; PLACEBO; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; FATTY ACID; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; AEROBIC METABOLISM; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ELEVATED BLOOD PRESSURE; ENZYME ACTIVITY; FATTY ACID OXIDATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; OBESITY; PRIORITY JOURNAL; SKELETAL MUSCLE; SYSTOLIC BLOOD PRESSURE; ADOLESCENT; CLINICAL TRIAL; HYPERTENSION; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BODY MASS INDEX; FATTY ACIDS; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; MUSCLE, SKELETAL; OBESITY; TETRAZOLES; YOUNG ADULT;

EID: 84924858722     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944714566426     Document Type: Article

References (27)

1. Abuissa H. Jones P. Marso S. O'Keefe J. (2005) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetesa meta-analysis of randomized clinical trials. J Am Coll Cardiol 46: 821–826.
2. Benson S. Pershadsingh H. Ho C. Chittiboyina A. Desai P. Pravenec M. et al. (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ–modulating activity. Hypertension 43: 993–1002.
3. Cortright R. Sandhoff K. Basilio J. Berggren J. Hickner R. Hulver M. et al. (2006) Skeletal muscle fat oxidation is increased in African-American and white women after 10 days of endurance exercise training. Obesity 14: 1201–1210.
4. Davy K. Hall J. (2004) Obesity and hypertension: two epidemics or one? Am J Physiol Regul Integr Comp Physiol 286: R803–R813
5. Després J. Lemieux I. Bergeron J. Pibarot P. Mathieu P. Larose E. et al. (2008) Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscl Throm Vas 28: 1039–1049.
6. Fogari R. Derosa G. Zoppi A. Rinaldi A. Lazzari P. Fogari E. et al. (2005) Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res 28: 209–214.
7. Frisard M. Mcmillan R. Marchand J. Wahlberg K. Wu Y. Voelker K. et al. (2010) Toll-like receptor 4 modulates skeletal muscle substrate metabolism. Am J Physiol Endocrinol Metab 298: 988–998.
8. Goossens G. Moors C. van der Zijl N. Venteclef N. Alili R. Jocken J. et al. (2012) Valsartan improves adipose tissue function in humans with impaired glucose metabolism: a randomized placebo-controlled double-blind trial. PloS ONE 7: e39930.
9. Henriksen E. Jacob S. Kinnick T. Teachey M. Krekler M. (2001) Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38: 884–890.
10. Holloway G. Thrush A. Heigenhauser G. Tandon N. Dyck D. Bonen A. et al. (2007) Skeletal muscle mitochondrial fat/CD36 content and palmitate oxidation are not decreased in obese women. Am J Physiol Endocrinol Metab 292: E1782–E1789
11. Hulver M. Berggren J. Carper M. Miyazaki M. Ntambi J. Hoffman E. et al. (2005) Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metab 2: 251–261.
12. Hulver M. Berggren J. Cortright R. Dudek R. Thompson R. Pories W. et al. (2003) Skeletal muscle lipid metabolism with obesity. Am J Physiol Endocrinol Metab 284: E741–E747.
13. Johnson M. Robinson M. Nair K. (2013) Skeletal muscle aging and the mitochondrion. Trends Endocrinol Metab 24: 247–256.
14. Kim J. Hickner R. Cortright R. Dohm G. Houmard J. (2000) Lipid oxidation is reduced in obese human skeletal muscle. Am J Physiol Endocrinol Metab 279: E1039–E1044.
15. Lteif A. Chisholm R. Gilbert K. Considine R. Mather K. (2012) Effects of losartan on whole body, skeletal muscle and vascular insulin responses in obesity / insulin resistance without hypertension. Diabetes Obes Metab 14: 254–261.
16. Marinik E. Frisard M. Hulver M. Davy B. Rivero J. Savla J. et al. (2013) Angiotensin II receptor blockade and insulin sensitivity in overweight and obese adults with elevated blood pressure. Ther Adv Cardiovasc Dis 7: 11–20.
17. Mitsuishi M. Miyashita K. Muraki A. Itoh H. (2009) Angiotensin II reduces mitochondrial content in skeletal muscle and affects glycemic Control. Diabetes 58: 710–717.
18. Miyoshi T. Doi M. Hirohata S. Kamikawa S. Usui S. Ogawa H. et al. (2011) Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. Heart Vessels 26: 408–413.
19. Moan A. Hoieggen A. Seljeflot I. Risanger T. Arnesen H. Kjeldsen S. (1996) The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 14: 1093–1097.
20. Moors C. Blaak E. van der Zijl N. Diamant M. Goossens G. (2013) The effects of long-term valsartan treatment on skeletal muscle fatty acid handling in humans with impaired glucose metabolism. J Clin Endocrinol Metab 98: E891–E896.
21. Nishimura H. Sanaka T. Tanihata Y. Naito T. Higuchi C. Otsuka K. (2008) Losartan elevates the serum high-molecular weight-adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. Hypertens Res 31: 1611–1618.
22. Rahmouni K. Correia M. Haynes W. Mark A. (2005) Obesity-associated hypertension new insights into mechanisms. Hypertension 45: 9–14.
23. Sloniger J. Saengsirisuwan V. Diehl C. Dokken B. Lailerd N. Lemieux A. et al. (2005) Defective insulin signaling in skeletal muscle of the hypertensive TG (MREN2) 27 rat. Am J Physiol Endocrinol Metab 288: E1074–E1081.
24. Suzuki H. Kanno Y. Sugahara S. Okada H. Nakamoto H. (2004) Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 43: 1056–1064.
25. Suzuki H. Nakamoto H. Okada H. Sugahara S. Kanno Y. (2002) A Selective angiotensin receptor antagonist, valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. Adv Peritoneal Dialysis 19: 59–66.
26. Vitale C. Mercuro G. Castiglioni C. Cornoldi A. Tulli A. Fini M. et al. (2005) Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 4: 6.
27. Wei Y. Sowers J. Clark S. Li W. Ferrario C. Stump C. (2008) Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-κB activation via NADPH oxidase. Am J Physiol Endocrinol Metab 294: E345–E351.